Here are four notes:
1. On average, the company has a “buy” rating and a target cost of $73.38.
2. The company’s director, Stuart Essig, sold 75,000 shares at an average cost of $64.32, for a total transaction of $4.8 million.
3. Integra recently reported second quarter revenue and full-year guidance after the SeaSpine spin-off is completed. The second quarter revenue increased 5.5 percent over the same period last year to $244.1 million.
4. Integra Lifesciences focuses on developing solutions in orthopedic extremity surgery, neurosurgery as well as reconstructive and general surgery.
More articles on devices:
Alphatec’s net revenue drops 12.3%: 8 key concepts
Tyber Medical to build new headquarters in Northampton County: 5 key points
ImageSmart eliminates harmful excessive imaging tests: 6 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
